AstraZeneca wins UK cost approval for longer use of heart drug

LONDON, Aug 12 (Reuters) - Long term use of AstraZeneca's

blood thinner Brilinta has been recommended as a

cost-effective option for treating patients after a heart

attack, Britain's healthcare...

Read more